Publications
Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2018 Aug 13. pii: S2213-8587(18)30136-0. doi: 10.1016/S2213-8587(18)30136-0. [Epub ahead of print] Review. PMID: 30115599
Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen M, Husain M. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2018 Oct 4. doi: 10.1111/dom.13553. [Epub ahead of print] PMID: 30284349
Bain SC, Klufas MA, Ho A, Matthews DR. Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13538. [Epub ahead of print] Review. PMID: 30226298
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2. PMID: 30072400
Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM; DEPICT-2 Investigators. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018 Sep;41(9):1938-1946. doi: 10.2337/dc18-0623. Epub 2018 Jul 19. PMID: 30026335
Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, Hicks D, James J, Newland-Jones P, Patel D, Viljoen A. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Ther. 2018 Oct;9(5):1757-1773. doi: 10.1007/s13300-018-0471-8. Epub 2018 Jul 23. Review. PMID: 30039249
Istepanian RSH, Casiglia D, Gregory JW. Mobile health (m-Health) for diabetes management. British Journal of Healthcare Management. 2017 March 16;23 (3), p. 102. doi: 10.12968/bjhc.2017.23.3.102
Powell WE, Hanna SJ, Hocter CN, Robinson E, Davies J, Dunseath GJ, Luzio S, Farewell D, Wen L, Dayan CM, Price DA, Ladell K, Wong FS. Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes. Diabetologia. 2018 Jun 7. doi: 10.1007/s00125-018-4651-x. [Epub ahead of print]. PMID: 29881878
Wong Y, Dickinson J, Perros P, Dayan C, Veeramani P, Morris D, Foot B, Clarke L. A British Ophthalmological Surveillance Unit (BOSU) study into dysthyroid optic neuropathy in the United Kingdom. Eye (Lond). 2018 Jun 18. doi: 10.1038/s41433-018-0144-x. [Epub ahead of print] Review. PMID: 29915191
Beltrami C, Simpson K, Jesky M, Wonnacott A, Carrington C, Holmans P, Newbury L, Jenkins R, Ashdown T, Dayan C, Satchell S, Corish P, Cockwell P, Fraser D, Bowen T. Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease. Am J Pathol. 2018 Jul 5. pii: S0002-9440(17)31144-6. doi: 10.1016/j.ajpath.2018.06.006. [Epub ahead of print]. PMID: 29981742